Optogenetics · Inherited retinal disease · NEJM
Optogenetic gene therapy plus light-projecting goggles restores limited vision in advanced retinitis pigmentosa
In an international study reported Oct 7, 2026 in NEJM (Sahel et al., doi 10.1056/NEJMoa2602215), ChrimsonR was delivered to retinal ganglion cells in the worse-seeing eye; custom goggles project amber-light pulses. Light sensitivity improved in 7 of 10 participants, and 4 of 8 who completed behavioral testing could find a doorway or follow a line with the goggles. The therapy was reported as safe.
Caveat: Small early-phase study; gains were limited (no reading or face recognition) and depend on the goggles. Not a restoration of normal sight.
Science News →
EurekAlert (Pitt release) →
Gene therapy · X-linked retinoschisis · Company data
Atsena reports ATSN-201 Phase 1/2 LIGHTHOUSE data in X-linked retinoschisis ahead of AAO 2026
Atsena (Oct 7, 2026) said most patients at the pivotal dose exceeded the FDA-referenced microperimetry threshold (>7 dB at 5+ loci), with structural and acuity gains building over time; 3 of 9 at the pivotal dose reached 20/40 or better. Phase 3 (Part C) enrollment is expected to complete by end of Q1 2027, topline in 1H 2028.
Caveat: Company-reported preliminary data from Parts A/B, not peer-reviewed; small cohort; pivotal Phase 3 still pending.
GlobeNewswire →
Aging biology · Senescence · Nature Aging
Age-related decline in chaperone-mediated autophagy impairs macrophage clearance of senescent cells
Published Oct 5, 2026 (open access). Loss of CMA gives senescent cells an aged-like secretory profile that suppresses macrophage CMA and their ability to engulf senescent cells. Pharmacological CMA activation reduced senescent-cell burden in aged mice and lessened disease in a pulmonary fibrosis mouse model.
Caveat: Mouse and cell data; no human trial of CMA activators for senescence yet.
Nature Aging →
AI · Aging knowledge graph · Scientific Reports
HALDxAI: an evidence-routed AI knowledge graph maps aging and longevity mechanisms
Published Oct 6, 2026. The team integrated 445,435 aging/longevity PubMed records with 19 biomedical databases into an Aging Knowledge Graph with multi-agent retrieval tied to sentence-level evidence. In expert review of 300 relations, all cited PMIDs resolved, 97.3% of shown evidence was attributable to the cited record, and 65.3% of claims were fully supported. TP53, mTOR and SIRT1 ranked as top bridge candidates.
Caveat: A hypothesis-generation tool; the authors note rankings reflect graph topology, not causality, and about a third of relation claims were not fully supported by their evidence.
Scientific Reports →
Gene therapy · Danon disease · Company update
Rocket outlines FDA-aligned pivotal Phase 2 path for RP-A501 in Danon disease
After an Oct 6, 2026 investor webinar, Rocket said the pivotal efficacy population is 12 male patients at a recalibrated dose of commercial-grade AAV9.LAMP2B; success needs at least 7 to meet both myocardial LAMP2 expression (≥Grade 1) and a ≥10% drop in LV mass index at 12 months. It reported sustained activity in Phase 1 follow-up and encouraging early safety in the first 3 patients on the modified protocol.
Caveat: Company-reported; the protocol was modified after earlier safety concerns, and the 3-patient safety data are very early.
Business Wire via StreetInsider →
